Eculizumab as first-line therapy for atypical hemolytic uremic syndrome

Pediatrics

Volumn 133, Issue 6, 2014, Pages

  Christmann, Martin ^a   Hansen, Matthias ^b   Bergmann, Carsten ^c   Schwabe, Dirk ^a   Brand, Jörg ^a   Schneider, Wilfried ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Clementine Kinderhospital   (Germany)

^c Bioscientia Center for Human Genetics   (Germany)

Author keywords

Atypical hemolytic uremic syndrome; Complement; Eculizumab; Infant

Indexed keywords

AMLODIPINE; ECULIZUMAB; ENALAPRIL; FUROSEMIDE; HAEMOPHILUS INFLUENZAE VACCINE; HEMOGLOBIN; HYDROCHLOROTHIAZIDE; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; METOPROLOL; NITROPRUSSIDE SODIUM; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HAEMOPHILUS INFECTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INFANT; INTENSIVE CARE UNIT; JAUNDICE; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; MENINGOCOCCOSIS; PALLOR; PERITONEAL DIALYSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT; ECULIZUMAB; INFANT;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; RENAL DIALYSIS;

EID: 84901835862     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-1787     Document Type: Article

References (20)

1. Noris M, Remuzzi G. Atypical hemolyticuremic syndrome. N Engl J Med. 2009;361 (17):1676-1687
2. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60
3. Scully M, Hunt BJ, Benjamin S, et al British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158(3):323-335
4. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8 (11):643-657
5. Bu F, Borsa N, Gianluigi A, Smith RJH. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol. 2012;2012:370426
6. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279 (Pubitemid 44232024)
7. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859
8. Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol. 2012;27(12):2327-2331
9. Giordano M, Castellano G, Messina G, et al. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics. 2012;130(5):e1385-e1388
10. Besbas N, Gulhan B, Karpman D, et al. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol. 2013;28(1): 155-158
11. Ariceta G, Besbas N, Johnson S, et al European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009; 24(4):687-696
12. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002;186(4):493-500 (Pubitemid 34876258)
13. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis. 2012;59(5):707-710
14. Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531-536
15. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):544-546
16. Lapeyraque A-L, Frémeaux-Bacchi V, Robitaille P. Effi cacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(4): 621-624
17. Dorresteijn EM, van de Kar NCAJ, Cransberg K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol. 2012;27 (7):1193-1195
18. De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C. Severe atypical HUS caused by CFH S1191L - case presentation and review of treatment options. Pediatr Nephrol. 2010;25(1):97-104
19. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181
20. Zuber J, Le Quintrec M, Krid S, et al French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337-3354